公开(公告)号：US20160022841A1

公开(公告)日：2016-01-28

申请号：US14875174

申请日：2015-10-05

申请人： THE GENERAL HOSPITAL CORPORATION

发明人： Richard H. MASLAND

IPC分类号： A61K48/00 ,  C12N7/00 ,  A61K9/00 ,  A61K38/17

CPC分类号： C07K14/705 ,  A01K2217/05 ,  A01K2267/03 ,  A61K9/0048 ,  A61K38/177 ,  A61K48/00 ,  A61K48/0075 ,  C12N7/00 ,  C12N2710/10043 ,  C12N2710/10071 ,  C12N2710/16043 ,  C12N2710/16071 ,  C12N2710/16243 ,  C12N2710/16271 ,  C12N2710/22043 ,  C12N2710/22071 ,  C12N2710/24043 ,  C12N2710/24071 ,  C12N2740/10043 ,  C12N2740/10071 ,  C12N2740/15043 ,  C12N2740/15071 ,  C12N2799/021 ,  C12N2799/04 ,  C12N2830/008

摘要： The invention provides compositions and methods of treating subjects afflicted with a photoreceptor disorder. Methods for treating a subject suffering from a disorder characterized by photoreceptor cell degeneration are provided, wherein a gene encoding a photosensitive protein is introduced into a retinal cell of a subject. In one aspect of the invention, the retinal cells which receive the photosensitive protein include non-photoreceptor cells such as horizontal cells, amacrine cells, bipolar cells, and ganglion cells.

摘要翻译： 本发明提供了治疗患有感光细胞病症的受试者的组合物和方法。 提供了治疗患有感光细胞变性特征性疾病的受试者的方法，其中将编码感光性蛋白质的基因导入受试者的视网膜细胞。 在本发明的一个方面，接受感光性蛋白质的视网膜细胞包括非感光细胞，例如水平细胞，无长突细胞，双极细胞和神经节细胞。

公开(公告)号：US20140227305A1

公开(公告)日：2014-08-14

申请号：US13818711

申请日：2011-08-25

申请人： Romana Lange-Ruiss ,  Gilbert Reisbach ,  Wolfgang Hammerschmidt ,  Reinhard Zeidler

发明人： Romana Lange-Ruiss ,  Gilbert Reisbach ,  Wolfgang Hammerschmidt ,  Reinhard Zeidler

IPC分类号： A61K39/245

CPC分类号： A61K39/245 ,  A61K39/12 ,  A61K2039/5258 ,  A61K2039/57 ,  A61K2039/575 ,  C07K14/005 ,  C07K2317/569 ,  C12N7/00 ,  C12N2710/16223 ,  C12N2710/16234 ,  C12N2710/16252 ,  C12N2710/16262 ,  C12N2710/16271

摘要： The present invention relates to a vaccine comprising a particle, said particle comprising (i) at least one Epstein-Barr virus (EBV) structural polypeptide, (ii) at least one EBV lytic polypeptide, (iii) membrane lipids, said particle being devoid of EBV DNA, wherein (a) the B-cell transformation capacity of one or more EBV polypeptides required for B-cell transformation as comprised in said particle is disabled while their immunogenicity is maintained; and/or (b) said particle is devoid of one or more EBV polypeptides required for B-cell transformation. Furthermore, the invention relates to a method for generating a particle, to a cell obtained in the method of the invention, a kit comprising the vaccine or the particle generated according to the method of the invention. Also, the invention relates to the use of the vaccine or the particle generated according to the method of the invention for generating CD8+ cells specific for an EBV antigen.

摘要翻译： 本发明涉及包含颗粒的疫苗，所述颗粒包含（i）至少一种爱泼斯坦 - 巴尔病毒（EBV）结构多肽，（ii）至少一种EBV溶解多肽，（iii）膜脂质，所述颗粒无缺陷 的EBV DNA，其中（a）包含在所述颗粒中的B细胞转化所需的一种或多种EBV多肽的B细胞转化能力在其免疫原性保持时被禁用; 和/或（b）所述颗粒缺乏B细胞转化所需的一种或多种EBV多肽。 此外，本发明涉及一种生成颗粒的方法，本发明方法获得的细胞包含根据本发明方法生成的疫苗或颗粒的试剂盒。 此外，本发明涉及根据本发明的方法产生的疫苗或颗粒用于产生对EBV抗原特异性的CD8 +细胞的用途。

公开(公告)号：US20050208022A1

公开(公告)日：2005-09-22

申请号：US11036629

申请日：2005-01-13

申请人： Richard Masland

发明人： Richard Masland

IPC分类号： A61K48/00 ,  C07K14/705 ,  C12N15/867

CPC分类号： C07K14/705 ,  A01K2217/05 ,  A01K2267/03 ,  A61K9/0048 ,  A61K38/177 ,  A61K48/00 ,  A61K48/0075 ,  C12N7/00 ,  C12N2710/10043 ,  C12N2710/10071 ,  C12N2710/16043 ,  C12N2710/16071 ,  C12N2710/16243 ,  C12N2710/16271 ,  C12N2710/22043 ,  C12N2710/22071 ,  C12N2710/24043 ,  C12N2710/24071 ,  C12N2740/10043 ,  C12N2740/10071 ,  C12N2740/15043 ,  C12N2740/15071 ,  C12N2799/021 ,  C12N2799/04 ,  C12N2830/008

摘要： The invention provides compositions and methods of treating subjects afflicted with a photoreceptor disorder. Methods for treating a subject suffering from a disorder characterized by photoreceptor cell degeneration are provided, wherein a gene encoding a photosensitive protein is introduced into a retinal cell of a subject. In one aspect of the invention, the retinal cells which receive the photosensitive protein include non-photoreceptor cells such as horizontal cells, amacrine cells, bipolar cells, and ganglion cells.

摘要翻译： 本发明提供了治疗患有感光细胞病症的受试者的组合物和方法。 提供了治疗患有感光细胞变性特征性疾病的受试者的方法，其中将编码感光性蛋白质的基因导入受试者的视网膜细胞。 在本发明的一个方面，接受感光性蛋白质的视网膜细胞包括非感光细胞，例如水平细胞，无长突细胞，双极细胞和神经节细胞。

公开(公告)号：US20170312355A1

公开(公告)日：2017-11-02

申请号：US15594167

申请日：2017-05-12

申请人： AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH ,  TESSA THERAPEUTICS PTE. LTD. ,  SINGAPORE HEALTH SERVICES PTE. LTD.

发明人： John CONNOLLY ,  Richard HOPKINS ,  Han Chong TOH

IPC分类号： A61K39/245 ,  C12Q1/70 ,  G01N33/574 ,  C12N7/00 ,  A61K39/00

CPC分类号： A61K39/245 ,  A61K35/17 ,  A61K2039/5158 ,  A61K2039/545 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2039/585 ,  C12N7/00 ,  C12N2710/16234 ,  C12N2710/16271 ,  C12Q1/68 ,  C12Q1/6886 ,  C12Q1/701 ,  C12Q1/705 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/158 ,  G01N33/574 ,  G01N33/57407 ,  G01N33/57423 ,  G01N33/57438 ,  G01N33/57446 ,  G01N2333/05 ,  G01N2333/521 ,  G01N2333/57 ,  G01N2800/52

摘要： A method for predicting whether a patient will be a long-term survivor on treatment of a disease by adoptive cell transfer (ACT), is disclosed comprising: (i) analysing a blood-derived sample obtained from the patient for one or more prognostic markers of long-term survival on treatment of a disease by ACT, and; (ii) based on the analysis of step (i), predicting whether the patient will be a long-term survivor on treatment of the disease by ACT. Also disclosed are methods for treating a patient by ACT, methods for selecting a patient for treatment by ACT, and methods for selecting a patient for treatment of a disease by ACT.

公开(公告)号：US20160296618A1

公开(公告)日：2016-10-13

申请号：US15077477

申请日：2016-03-22

申请人： HELMHOLTZ ZENTRUM MUNCHEN DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH)

发明人： Romana Ruiss ,  Gilbert Reisbach ,  Wolfgang Hammerschmidt ,  Reinhard Zeidler

IPC分类号： A61K39/245 ,  C07K14/005 ,  C12N7/00

CPC分类号： A61K39/245 ,  A61K39/12 ,  A61K2039/5258 ,  A61K2039/57 ,  A61K2039/575 ,  C07K14/005 ,  C07K2317/569 ,  C12N7/00 ,  C12N2710/16223 ,  C12N2710/16234 ,  C12N2710/16252 ,  C12N2710/16262 ,  C12N2710/16271

摘要： The present invention relates to a vaccine comprising a particle, said particle comprising (i) at least one Epstein-Barr virus (EBV) structural polypeptide, (ii) at least one EBV lytic polypeptide, (iii) membrane lipids, said particle being devoid of EBV DNA, wherein (a) the B-cell transformation capacity of one or more EBV polypeptides required for B-cell transformation as comprised in said particle is disabled while their immunogenicity is maintained; and or (b) said particle is devoid of one or more EBV polypeptides required for B-cell transformation. Furthermore, the invention relates to a method for generating a particle, to a cell obtained in the method of the invention, a kit comprising the vaccine or the particle generated according in the method of the invention. Also, the invention relates to the use of the vaccine or the particle generated according to the method of the invention for generating CD8+ cells specific for an EBV antigen.

摘要翻译： 本发明涉及包含颗粒的疫苗，所述颗粒包含（i）至少一种爱泼斯坦 - 巴尔病毒（EBV）结构多肽，（ii）至少一种EBV溶解多肽，（iii）膜脂质，所述颗粒无缺陷 的EBV DNA，其中（a）包含在所述颗粒中的B细胞转化所需的一种或多种EBV多肽的B细胞转化能力在其免疫原性保持时被禁用; 和（b）所述颗粒没有B细胞转化所需的一种或多种EBV多肽。 此外，本发明涉及一种生成颗粒的方法，本发明方法获得的细胞，包含根据本发明方法生成的疫苗或颗粒的试剂盒。 此外，本发明涉及根据本发明的方法产生的疫苗或颗粒用于产生对EBV抗原特异性的CD8 +细胞的用途。

公开(公告)号：US09434781B2

公开(公告)日：2016-09-06

申请号：US11036629

申请日：2005-01-13

申请人： Richard H. Masland

发明人： Richard H. Masland

IPC分类号： A61K48/00 ,  C12N15/63 ,  C07K14/705 ,  A01K67/00

CPC分类号： C07K14/705 ,  A01K2217/05 ,  A01K2267/03 ,  A61K9/0048 ,  A61K38/177 ,  A61K48/00 ,  A61K48/0075 ,  C12N7/00 ,  C12N2710/10043 ,  C12N2710/10071 ,  C12N2710/16043 ,  C12N2710/16071 ,  C12N2710/16243 ,  C12N2710/16271 ,  C12N2710/22043 ,  C12N2710/22071 ,  C12N2710/24043 ,  C12N2710/24071 ,  C12N2740/10043 ,  C12N2740/10071 ,  C12N2740/15043 ,  C12N2740/15071 ,  C12N2799/021 ,  C12N2799/04 ,  C12N2830/008

摘要： The invention provides compositions and methods of treating subjects afflicted with a photoreceptor disorder. Methods for treating a subject suffering from a disorder characterized by photoreceptor cell degeneration are provided, wherein a gene encoding a photosensitive protein is introduced into a retinal cell of a subject. In one aspect of the invention, the retinal cells which receive the photosensitive protein include non-photoreceptor cells such as horizontal cells, amacrine cells, bipolar cells, and ganglion cells.

摘要翻译： 本发明提供了治疗患有感光细胞病症的受试者的组合物和方法。 提供了治疗患有感光细胞变性特征性疾病的受试者的方法，其中将编码感光性蛋白质的基因导入受试者的视网膜细胞。 在本发明的一个方面，接受感光性蛋白质的视网膜细胞包括非感光细胞，例如水平细胞，无长突细胞，双极细胞和神经节细胞。

公开(公告)号：US20240270796A1

公开(公告)日：2024-08-15

申请号：US18494219

申请日：2023-10-25

申请人： THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.

发明人： Xinle Cui ,  Clifford M. Snapper

IPC分类号： C07K14/005 ,  A61K39/245 ,  A61K39/25 ,  A61P31/22 ,  C12N7/00

CPC分类号： C07K14/005 ,  A61K39/245 ,  A61K39/25 ,  A61P31/22 ,  C12N7/00 ,  C12N2710/16034 ,  C12N2710/16071 ,  C12N2710/16134 ,  C12N2710/16171 ,  C12N2710/16234 ,  C12N2710/16271 ,  C12N2710/16334 ,  C12N2710/16371 ,  C12N2710/16634 ,  C12N2710/16671 ,  C12N2710/16734 ,  C12N2710/16771

摘要： Provided are antigenic compositions and uses thereof that include at least two human herpesvirus (HHV) polypeptides involved in mediating HHV binding, fusion, and entry into host cells, such as gp350, gH, gL, and gB, or nucleic acids encoding the polypeptides. The two HHV polypeptides comprise any combination of: a gB polypeptide; a gp350 polypeptide; a gL polypeptide; and a gH polypeptide, and optionally any one or more of the following polypeptides: gp42, gM, gN, gl, gC, gE, gD, ORF68, BMRF-2, BDLF2, UL128, UL130, UL131A, and gpK8.1. Also disclosed are methods of inducing an immune response or treating or preventing O an HHV infection in a subject by administering to the subject at least two of the HHV polypeptides or nucleic acid(s) encoding the same. Methods of passively transferring immunity using high-titer anti-HHV antibodies or immune cells are also disclosed.

公开(公告)号：US12005115B2

公开(公告)日：2024-06-11

申请号：US16922322

申请日：2020-07-07

申请人： The USA, as represented by the Secretary, Dept. of Health and Human Services

发明人： Masaru Kanekiyo ,  Gary J. Nabel ,  Jeffrey Cohen ,  Wei Bu

IPC分类号： A61K39/245 ,  A61K39/12 ,  C07K14/00 ,  C07K14/005 ,  C07K14/195 ,  C07K16/08 ,  C12N7/00 ,  A61K39/00

CPC分类号： A61K39/245 ,  A61K39/12 ,  C07K14/00 ,  C07K14/005 ,  C07K14/195 ,  C07K16/085 ,  C12N7/00 ,  A61K2039/55505 ,  A61K2039/575 ,  A61K2039/64 ,  C07K2317/33 ,  C07K2317/76 ,  C07K2319/00 ,  C07K2319/40 ,  C07K2319/735 ,  C12N2710/16222 ,  C12N2710/16234 ,  C12N2710/16271

摘要： Vaccines are provided that elicit neutralizing antibodies to Epstein-Barr virus (EBV). Some vaccines comprise nanoparticles that display envelope proteins from EBV on their surface. The nanoparticles comprise fusion proteins comprising a monomeric subunit of a self-assembly protein, such as ferritin, joined to at least a portion of an EBV envelope protein. The fusion proteins self-assemble to form the envelope protein-displaying nanoparticles. Such vaccines can be used to vaccinate an individual against infection by different types of Epstein-Barr viruses as well as Epstein-Barr viruses that are antigenically divergent from the virus from which the EBV envelope protein was obtained. Also provided are fusion proteins and nucleic acid molecules encoding such proteins.

公开(公告)号：US11773139B2

公开(公告)日：2023-10-03

申请号：US16770963

申请日：2018-12-14

申请人： GLAXOSMITHKLINE BIOLOGICALS SA

发明人： Stefania Capone ,  Antonella Folgori ,  Armin Lahm ,  Benjamin Wizel

IPC分类号： C07K14/005 ,  A61K39/245 ,  C12N7/00 ,  A61K39/00

CPC分类号： C07K14/005 ,  A61K39/245 ,  C12N7/00 ,  A61K2039/70 ,  C12N2710/16222 ,  C12N2710/16234 ,  C12N2710/16271

摘要： The invention provides Epstein-Barr Virus antigen polynucleotides, polypeptides and vectors; as well as immunogenic compositions comprising the same. It includes the use of Epstein-Barr Virus antigen constructs to produce vaccines for treating and preventing Epstein-Barr Virus infections and Epstein-Barr Virus-associated diseases, such as multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus.

公开(公告)号：US20180078634A1

公开(公告)日：2018-03-22

申请号：US15558942

申请日：2016-03-16

申请人： THE UNIVERSITY OF MASSACHUSETTS

发明人： Javier Gordon Ogembo ,  Trudy Morrison

IPC分类号： A61K39/245 ,  C12N7/00 ,  A61K39/12 ,  G01N33/574

CPC分类号： A61K39/245 ,  A61K39/12 ,  A61K2039/5256 ,  A61K2039/5258 ,  A61K2039/575 ,  A61K2039/585 ,  A61K2039/70 ,  C12N7/00 ,  C12N2710/16222 ,  C12N2710/16223 ,  C12N2710/16234 ,  C12N2710/16271 ,  C12N2710/20022 ,  C12N2710/20023 ,  C12N2710/20034 ,  C12N2710/20071 ,  C12N2760/18122 ,  C12N2760/18123 ,  C12N2760/18134 ,  C12N2760/18171 ,  G01N33/574 ,  G01N2333/05

摘要： The present invention relates to prophylactic and/or therapeutic vaccines that contain Newcastle disease virus (NDV) virus-like particles (VLPs) comprising one or more Epstein-Barr Virus (EBV) antigens. In one embodiment, the invention provides a recombinant virus-like particle (VLP) comprising, in operable combination, a) Newcastle disease virus (NDV) matrix (M) protein, and b) one or more Epstein-Barr Virus (EBV) antigens. The invention's prophylactic and/or therapeutic vaccines are useful for preventing and/or treating infection with EBV and/or disease associated Epstein-Barr Virus, such as cancer.